MedPath

Study on bimatoprost eye solution vs tacrolimus ointment in treatment of stable vitiligo.

Phase 4
Conditions
Health Condition 1: L80- Vitiligo
Registration Number
CTRI/2024/01/061673
Lead Sponsor
Eras Lucknow Medical College and Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Stable vitiligo patients involving less than 5 % of body surface area attending the dermatology OPD at Era Lucknow Medical College and Hospital

Exclusion Criteria

1. Vitiligo patients who took treatment in last 3 months

2. Patient having hypersensitivity to tacrolimus ointment and bimatoprost ophthalmic solution.

3. Pregnant and lactating women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the therapeutic response of topical bimatoprost (0.03%) ophthalmic solution with tacrolimus (0.1%) ointment in cases of stable vitiligo.Timepoint: 0,4,8,12 weeks
Secondary Outcome Measures
NameTimeMethod
1.To study the clinical response of bimatoprost (0.03%) ophthalmic solution on stable vitiligo. <br/ ><br>2.To study the clinical response of tacrolimus (0.1%) ointment on stable vitiligo. <br/ ><br>3.To identify any adverse effects associated with the use of topical bimatoprost (0.03%) ophthalmic solution and tacrolimus ointment (0.1%) in cases of stable vitiligo. <br/ ><br>Timepoint: 0,4,8,12 weeks
© Copyright 2025. All Rights Reserved by MedPath